Company Overview

Incyte Corporation is a global biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Headquartered in Wilmington, Delaware, the company was incorporated in 1991 and operates in the United States, Europe, Canada, and Japan. Incyte is built on the principle of investing in strong science and R&D excellence to create new solutions that positively impact patients' lives, primarily focusing on hematology and oncology, as well as inflammation and autoimmunity therapeutic areas.

Market Capitalization and Share Information

Incyte's market capitalization stands at $16.83 billion as of August 20, 2025. The company's market cap has seen a significant increase of 35.58% over the past year. Incyte has 195.28 million shares outstanding.

Key Products Portfolio

Primary Revenue Drivers

- JAKAFI® (ruxolitinib): The company's cornerstone product, approved for the treatment of:

- Intermediate or high-risk myelofibrosis

- Polycythemia vera

- Steroid-refractory acute graft-versus-host disease

- OPZELURA® (ruxolitinib) cream: Approved for the topical treatment of:

- Atopic dermatitis

- Vitiligo

Additional Marketed Products

The company also markets:

- MONJUVI®/MINJUVI® (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma.

- PEMAZYRE® (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms.

- ICLUSIG® (ponatinib), a kinase inhibitor for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia.

- ZYNYZ™ (retifanlimab-dlwr) for adults with metastatic or recurrent locally advanced Merkel cell carcinoma.

- NIKTIMVO® (axatilimab-csfr) for treating chronic graft-versus-host disease.

Financial Performance

Recent Financial Results

2024 Full Year Performance:

- Total revenues for 2024 reached $4.24 billion, an increase of 14.76% compared to $3.70 billion in the previous year.

- Q4 2024 revenues were $1.2 billion (+16% year-over-year), with full-year 2024 revenues at $4.2 billion (+15% year-over-year).

Key Product Revenue (FY 2024):

- Jakafi: Net revenues of $2.8 billion (+8% year-over-year) for FY2024, including $773 million in Q4 (+11% year-over-year).

- Opzelura: Net revenues of $508 million (+50% year-over-year) for FY2024, including $162 million in Q4 (+48% year-over-year).

Q1 2025 Performance:

- Total revenues for the first quarter of 2025 were $1.053 billion, a 20% increase year-over-year.

- Jakafi®: Net product revenues were $709 million, a 24% increase year-over-year.

- Opzelura®: Net product revenues were $119 million, a 38% increase year-over-year.

2025 Financial Guidance

- Jakafi Revenue Guidance: Raised to $2.950 - $3.000 billion.

- Opzelura Revenue Guidance: Maintained at $630 - $670 million.

- R&D Expense Guidance: $1.93 billion to $1.96 billion.

- SG&A Expense Guidance: $1.28 billion to $1.31 billion.

Pipeline and Development

Clinical Stage Programs

Incyte's pipeline includes several promising clinical-stage programs:

- INCB123667 (CDK2) for ovarian cancer.

- INCB161734 (KRASG12D) for various cancers.

- INCA33890 (TGFßR2xPD-1) for solid tumors.

- Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS).

- Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, asthma, and chronic spontaneous urticaria.

- INCB000262 and INCB000547 (MRGPRX2 and MRGPRX4) for systemic immune and neuro-immune disorders.

- INCA034460 (anti-CD122) for vitiligo.

- Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive.

2025 Strategic Outlook

2025 is anticipated to be a significant year with:

- Four new product launches.

- Four pivotal study readouts.

- At least three Phase 3 study initiations.

- Seven proof-of-concept study readouts.

- A key development includes ruxolitinib extended-release meeting FDA bioequivalence criteria, with submission planned by year-end 2025.

Key Financial Metrics

- Trailing PE Ratio: 19.83

- Forward PE Ratio: 13.12

- Return on Equity (ROE): 24.30%

- Return on Invested Capital (ROIC): 16.67%

- 52-Week Stock Performance: +31.82%

- Last 12 Months Revenue: $4.58 billion

- Last 12 Months Profit: $870.87 million

Strategic Partnerships

Incyte has a strategic collaboration with Genesis Therapeutics, Inc. to develop novel small molecule medicines utilizing AI technology.

Business Operations and Financial Health

Incyte sells its products through specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company maintains a robust financial position with $2.2 billion in cash and no debt as of the end of 2024.

Incyte continues to demonstrate strong operational performance, driven by its established product portfolio, particularly Jakafi and the rapidly growing Opzelura franchise. The company is also making significant investments in research and development to expand its pipeline and therapeutic reach across multiple disease areas.